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Valorisation 
According to Appendix 4 of the Regulation Governing the Attainment of Doctoral 
Degrees (Maastricht University 2013), knowledge valorisation refers to the 
“process of creating value from knowledge, by making knowledge suitable 
and/or available for social and economic use and by making knowledge suitable 
for translation into competitive products, services, processes and new 
commercial activities”. Five questions must be answered in this valorisation 
addendum: (1) what is the socio-economic relevance of the research results? 
(relevance); (2) for whom, outside the peer researchers, are the results 
relevant? (target population); (3) which concrete services/products can be 
obtained? (products); (4) what is the innovation value of the results? 
(innovation); and (5) what are the marketing strategies that can be applied? 
(planning and realisations).  
Socio-economic relevance 
The results of this thesis show that (1) patients with a near complete response 
(ncCR) after CRT can develop a clinical complete response (cCR) after another 
6-12 weeks waiting, with no impact on the oncological outcome; (2) follow-up 
with MRI after Transanal Endoscopic Microsurgery (TEM) for rectal cancer is 
feasible; (3) patients in a W&W-strategy show a better QoL, compared to 
patients treated with CRT and TME, and show less functional problems; (4) the 
validation of the Dutch version of the Low Anterior Resection Syndrome (LARS) 
score, and (5) the W&W-strategy is a cost-saving strategy compared to CRT and 
TME. 
Because of the feasibility of MRI as an follow-up technique for patients who 
underwent TEM for rectal cancer, an extra modality can be added in the follow-
up of these patients. Studies have to show if the combination of endoscopy and 
MRI are the best practice in follow-up for TEM patients. The results of point 1, 3 
and 5 are all based on patients with locally advanced rectal cancer who were 
treated with neoadjuvant CRT as part of the national guidelines. Maybe this 
organ-preservation could also be feasible for patients with an earlier stage of 
rectal cancer. Studies (TESAR and STARTREC) have to show the results in this 
group of patients. Since the W&W-strategy is a cost-effective strategy, health 
insurance companies can accept the W&W-treatment. The Dutch version of the 
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LARS-score ensures a good and short scoring system for bowel dysfunction 
after low anterior resection (LAR).  
Target population 
National guidelines state that all patients with locally advanced rectal cancer are 
treated with neo-adjuvant CRT followed by a surgical resection. 15-20% of these 
patients develop a cCR after CRT and could be considered for an organ-
preserving treatment, the so called watch-and-wait policy. As mentioned before, 
organ-preservation could also be feasible for patients with an earlier stage of 
rectal cancer. Studies (TESAR and STARTREC) have to show the results in this 
group of patients. The Dutch version of the LARS-score can be used in all rectal 
cancer patients with Dutch as mother tongue. The questionnaire was developed 
as a scoring system for bowel dysfunction after LAR for rectal cancer, on the 
basis of symptoms and impact on QoL.  
Products 
There are no new products that have been developed with the results of this 
thesis.  
Innovation and future 
The W&W-policy, an organ preserving strategy for a selected group of rectal 
cancer patients has proven to be feasible and oncologically safe. More data and 
longer follow-up are necessary to confirm these results. In 2014 a multicentre 
collaboration has started to obtain these results. This international watch-and-
wait database centralizes the data of all main organ-preservation pioneers. The 
first results will be published soon. A recent multicentre study is started to obtain 
more data of Dutch W&W-patients.  
Data on functional outcome and quality of life is scarce. A prospective study has 
started to the quality of life and functional outcome of these patients at several 
time-points during a 5-year follow-up. In the recently started Dutch multicentre 
study, these results will also be obtained. The Dutch version of the LARS-score 
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has been validated, as shown in this thesis. This questionnaire shall be 
translated and validated in more languages.  
Cost-effectiveness has to be studied in an Markov simulation with a combination 
of data on costs and QoL. 
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